Akums Drugs & Pharmaceuticals Ltd (AKUMS)
🎯 Key Takeaways
- Akums Drugs & Pharmaceuticals is transitioning from a newly listed pharmaceutical manufacturer into a diversifying specialty chemical and cosmetics player, leveraging its IPO proceeds for strategic expansion. The company has demonstrated strong profitability growth and capital efficiency, with ROCE at 15.
- Revenue grew 0.8% QoQ to ₹1,167 in Q1FY27.
- ⚠️ The ₹600.92 million tax demand remains under appeal, posing a potential contingent liability that could affect profitability if unresolved.
- Market Cap
- ₹12,595
- P/E Ratio
- 42.0
- P/B Ratio
- 3.80
- ROE
- 8.8%
- ROCE
- 15.4%
- Debt/Equity
- 0.02
- Div Yield
- 0.37%
- Promoter
- 75.3%
📖 The Story
Akums Drugs & Pharmaceuticals is transitioning from a newly listed pharmaceutical manufacturer into a diversifying specialty chemical and cosmetics player, leveraging its IPO proceeds for strategic expansion. The company has demonstrated strong profitability growth and capital efficiency, with ROCE at 15.4% and minimal debt, but its elevated P/E of 40.8 reflects market expectations of sustained momentum. It is currently in a growth phase, marked by aggressive reinvestment and portfolio diversification.
📰 What's Happening
In Q1 FY2026, Akums approved the acquisition of Oriflame India’s manufacturing business for ₹56 crores to enter the color cosmetics and wellness segment, targeting completion by 31 August 2026. The Board also declared a ₹2 per share dividend and reallocated unutilized IPO funds to general corporate purposes and acquisitions, maintaining compliance with the 25% cap. CRISIL confirmed full deployment of ₹6,421.80 million IPO proceeds by June 30, 2026, across debt repayment, working capital, and inorganic growth, with no deviations. Dividend of ₹3 per share was approved for payment on August 8, 2026.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1,018 | 1,160 | 1,158 | 1,167 |
| Operating Profit | 57 | 107 | 112 | 134 |
| OPM % | 5.6% | 9.3% | 9.6% | 11.4% |
| Net Profit | 43 | 68 | 81 | 101 |
| EPS | ₹2.66 | ₹4.33 | ₹5.53 | ₹6.53 |
Revenue grew steadily from ₹1,018 crore in September 2025 to ₹1,167 crore in June 2026, while net profit surged from ₹43 crore to ₹101 crore over the same period, indicating strong operational leverage. Operating margins improved from 5.6% to 11.4%, and net profit margins rose significantly, reflecting better cost control and scale benefits. Despite flat revenue growth sequentially, profitability expanded sharply, suggesting efficient scaling. The company has consistently deployed capital from its IPO, with no unused proceeds remaining, supporting both inorganic growth and shareholder returns.
🔮 Management Outlook & What's Next
Management has not provided formal forward guidance in the latest filings. However, the Board’s actions — including dividend approval, acquisition announcements, and capital allocation — signal confidence in near-term cash flow stability and growth prospects. The focus remains on executing the Oriflame integration and leveraging new manufacturing capacity to expand into higher-margin segments like cosmetics and wellness.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 31 | 31 | 31 | 31 |
| Reserves | 3,016 | 2,803 | 3,283 | 3,118 |
| Borrowings | 88 | 530 | 73 | 90 |
| Total Liabilities | 4,113 | 4,270 | 5,447 | 5,159 |
| Fixed Assets | 1,390 | 1,249 | 1,457 | 1,410 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 4,113 | 4,270 | 5,447 | 5,159 |
The balance sheet shows a stable capital structure with equity of ₹31 crore and reserves growing from ₹3,016 crore to ₹3,283 crore as of March 2026, while borrowings remain low at ₹73–90 crore. Total assets have increased steadily, indicating capital deployment into operations and acquisitions without over-leveraging. The company is prioritizing reinvestment in manufacturing capacity and working capital, while maintaining strong equity buffers and minimal debt, reflecting a conservative and disciplined balance sheet approach.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +1,181 |
| Investing | -930 |
| Financing | +34 |
| Net Cash Flow | +285 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 75.3% | 75.3% | 75.3% | 75.3% |
| FII | 2.3% | 1.1% | 1.4% | 1.9% |
| DII | 9.3% | 14.4% | 14.3% | 13.4% |
| Public | 5.0% | 5.5% | 5.3% | 5.6% |
| # Shareholders | 75,365 | 76,869 | 72,589 | 70,289 |
Institutional investor interest has declined slightly, with FII holdings dropping from 2.28% in Q2 FY26 to 1.37% in Q4 FY26, while DII holdings rose from 9.28% to 14.35%, suggesting growing domestic institutional confidence. Promoter holding remains stable at 75.26%. The rising number of public shareholders (from 75,365 to 72,589) and consistent promoter stake indicate broadening retail interest. No pledging or significant dilution is evident, and the shareholder base is gradually diversifying.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. The ₹600.92 million tax demand remains under appeal, posing a potential contingent liability that could affect profitability if unresolved. 2. Integration risk associated with the Oriflame India acquisition, including execution delays or underperformance of the acquired business, could impact margins and cash flows. 3. High valuation (P/E of 40.8) may limit upside if growth does not sustain, especially with no formal guidance provided. 4. Dependence on a few key customers or regulatory changes in the pharmaceutical or cosmetics sector could pose concentration risks.
📋 Recent Filings
- Announcement2026-09-25Akums Drugs & Pharmaceuticals announced that its insider trading compliance window closes on October 1, 2026, ahead of the upcoming quarterly financia…
- 🔴 Announcement2026-09-23Akums Drugs & Pharmaceuticals announced its schedule for two institutional investor meetings on September 28-29, 2026, in Mumbai, offering one-on-one …
- 🔴 Announcement2026-09-16Akums Drugs & Pharmaceuticals announced its participation in a scheduled investor and analyst meet on September 22, 2026, at 10:00 AM IST, including a…
- 🔴 Announcement2026-09-03Akums Drugs & Pharmaceuticals announced it received an ESG rating of 65 from NSE Sustainability for fiscal year 2025-26, based on publicly available i…
- Announcement2026-08-25Akums Drugs and Pharmaceuticals announced its participation in scheduled investor and analyst meetings, including an Elara India Dialogue event on Sep…
- Announcement2026-08-24Akums Drugs and Pharmaceuticals announced that its management cannot attend the scheduled Antique Stock Broking investor-analyst meet on August 25, 20…
- Announcement2026-08-13Akums Drugs and Pharmaceuticals announced its participation in an Antique Healthcare investor conference on August 25, 2026, starting at 09:00 AM IST …
- 🔴 offer document2026-08-10CRISIL Ratings' August 10, 2026 monitoring report confirms Akums Drugs and Pharmaceuticals Limited fully utilized IPO proceeds of Rs 6,421.80 million …
- Announcement2026-08-10Akums Drugs and Pharmaceuticals announced an audio recording of its investor conference call held on August 10, 2026 at 12:00 PM IST to discuss un-aud…
- Announcement2026-08-08Akums Drugs and Pharmaceuticals reported Q1 FY27 revenue of **₹1,167 crores** (+13.9% YoY) driven by CDMO growth, while EBITDA rose **35.4% YoY** to *…
🧠 Analyst's Read
Akums is executing a clear growth strategy through inorganic expansion and capital recycling, supported by strong profitability and a clean balance sheet. While financial trends are encouraging, the lack of forward guidance and elevated valuation warrant caution. Investors should monitor the successful integration of the Oriflame acquisition and resolution of the tax appeal as key near-term catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AKUMS files new disclosures
Track AKUMS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AKUMS — FreeFree account · 2 AI queries/day